Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 8, 2020 in Stroke | 0 comments

In a nutshell

This study compared different treatments for the prevention of blood lots and stroke in patients with anti-phospholipid syndrome (APS). They found that warfarin (Coumadin) is more effective at preventing stroke than other blood thinners.

Some background

APS is a disorder of the immune system which leads to excessive blood clotting. Blood clots can form in any artery or vein leading to leg and lung clots, stroke, or miscarriage. Treatments to prevent clots include anticoagulants (which alter the process of blood clotting) and antiplatelets (which stop cells in the blood from clumping together). There are two types of anticoagulants: warfarin and NOACs. Warfarin interferes with vitamin K which is important for blood clotting. NOACs are a  family of drugs that interfere with a protein involved with blood clotting. Rivaroxaban (Xarelto) is a member of the NOAC family.

NOACs are now being used more frequently because unlike warfarin they do not need regular monitoring. However, it is not clear whether they are as effective as warfarin in the management of APS.

Methods & findings

This study compiled the results of 8 studies with a total of 811 participants. Participants were treated with different combinations of blood thinners and monitored for the development of clot-related events such as stroke or miscarriage. 

Patients taking rivaroxaban were 14.13 times more likely to suffer a stroke than patients taking warfarin. There was no significant difference in the risk of bleeding between rivaroxaban and warfarin.

Patients taking high-dose warfarin had the same risk of clots as those taking standard-dose warfarin. However, they were more likely to have problems with bleeding. 

Standard-dose warfarin combined with antiplatelets such as aspirin was associated with an increased risk of both clotting and bleeding compared to standard-dose warfarin alone.

The bottom line

This study showed that standard dose warfarin may be the safest and most effective treatment for clot prevention in APS. 

The fine print

Some of the evidence included in this study was not of high quality. More studies are needed to confirm these results.  

Published By :

Cochrane database of systematic reviews

Date :

Oct 12, 2020

Original Title :

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

click here to get personalized updates